Fingerlakes Wealth Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.27M Buy
1,059
+11
+1% +$11.2K 0.68% 37
2026
Q1
$964K Buy
1,048
+16
+2% +$16.2K 0.64% 40
2025
Q4
$1.11M Sell
1,032
-2
-0.2% -$1.91K 0.71% 39
2025
Q3
$789K Sell
1,034
-68
-6% -$50.6K 0.51% 44
2025
Q2
$859K Sell
1,102
-17
-2% -$13.2K 0.64% 39
2025
Q1
$925K Buy
1,119
+5
+0.4% +$4.16K 0.79% 36
2024
Q4
$860K Sell
1,114
-5
-0.4% -$4.14K 0.69% 39
2024
Q3
$991K Sell
1,119
-37
-3% -$33.3K 0.82% 37
2024
Q2
$1.05M Sell
1,156
-3
-0.3% -$2.4K 0.94% 34
2024
Q1
$902K Hold
1,159
0.87% 35
2023
Q4
$676K Buy
1,159
+2
+0.2% +$1.17K 0.73% 36
2023
Q3
$621K Buy
1,157
+2
+0.2% +$1.03K 0.76% 35
2023
Q2
$542K Buy
1,155
+2
+0.2% +$839 0.62% 46
2023
Q1
$396K Buy
1,153
+2
+0.2% +$675 0.49% 58
2022
Q4
$421K Buy
1,151
+3
+0.3% +$1.06K 0.58% 49
2022
Q3
$371K Sell
1,148
-21
-2% -$6.65K 0.54% 56
2022
Q2
$379K Sell
1,169
-32
-3% -$9.61K 0.52% 62
2022
Q1
$344K Buy
1,201
+4
+0.3% +$1.03K 0.4% 66
2021
Q4
$333K Buy
+1,197
New +$303K 0.37% 70

Other funds holding LLY

Fingerlakes Wealth Management's LLY Position: Q2 2026 in Review

Fingerlakes Wealth Management increased its Eli Lilly (LLY) stake by 1% in Q2 2026, buying an estimated $11.2K and bringing the position to 1,059 shares worth $1.27M. The position accounts for 0.68% of the portfolio, ranked #37.

Fingerlakes Wealth Management first reported a position in LLY in Q4 2021 and has held it in 19 quarters since. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Fingerlakes Wealth Management held 1,059 shares of Eli Lilly worth $1.27M as of Q2 2026.
  • Fingerlakes Wealth Management bought 11 Eli Lilly shares in Q2 2026, an estimated $11.2K.
  • Eli Lilly made up 0.68% of Fingerlakes Wealth Management's portfolio in Q2 2026, its #37 holding.
  • Fingerlakes Wealth Management first reported a position in Eli Lilly in Q4 2021 and has held it in 19 quarters since.
  • 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Fingerlakes Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.